N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT

Title:

N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT

Document Type and Number:

WIPO Patent Application WO/2021/066559

Kind Code:

A1

Abstract:

N-(1H-imidazol-2-yl)benzamide compound of formula (I), or a pharmaceutically acceptable salt, a prodrug, a solvate, or a stereoisomer thereof which is a novel compound exhibiting excellent inhibitory activity against IRAK-4, can be used without side effects for efficient prevention and treatment of diseases mediated by IRAK-4 receptors, particularly autoimmune diseases or lymphomas.

More Like This:

JPH0655738	INDUSTRIAL APPLICABILITY: Indazole-3-carboxamide derivative and a serotonin 3 receptor antagonist containing the same as an active ingredient.
JP2008501767	Indole derivative as an antiviral agent
WO/2006/108487	(LH-IND0L-7-YL)-( (PYRIMIDIN-2 -YL-AMINO) METHANONE DERIVATIVES AND RELATED COMPOUNDS AS IGF-RL INHIBITORS FOR TREATING CANCER

Inventors:

CHUNG JAEUK (KR)
KIM SUNMI (KR)
CHO HANYANG (KR)
MIN JIYOUNG (KR)

Application Number:

PCT/KR2020/013397

Publication Date:

April 08, 2021

Filing Date:

September 29, 2020

Export Citation:

Click for automatic bibliography generation Help

Assignee:

KAINOS MEDICINE INC (KR)

International Classes:

C07D403/12; A61K31/4178; A61K31/422; A61K31/4439; A61K31/454; A61P35/00; A61P37/00; C07D401/14; C07D403/14; C07D413/12

Domestic Patent References:

WO2003030902A1	2003-04-17
WO2018184019A1	2018-10-04
WO2014181287A1	2014-11-13
WO2005110994A2	2005-11-24

Foreign References:

CN102617578A

2012-08-01

Other References: